CLINICAL_TRIALS
trial_result
· 2012-08-21
Clinical Trial Update: Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation [Phase 3]
Summary
Phase 3 trial results for ivacaftor in children aged 6 to 11 with the G551D CF mutation; results were posted after completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2012-08-21